Anwulignan Ameliorates the Intestinal Ischemia/Reperfusion

Area of Science:

• Pharmacology and Toxicology
• Gastroenterology
• Biochemistry

Background:

• Intestinal ischemia/reperfusion (II/R) injury is a serious clinical condition with limited treatment options.
• Anwulignan, a monomer compound from *Schisandra sphenanthera*, has shown potential therapeutic properties.
• Understanding the protective mechanisms of anwulignan against II/R injury is crucial for its clinical application.

Purpose of the Study:

• To investigate the protective effects of anwulignan on intestinal ischemia/reperfusion (II/R) injury in a rat model.
• To elucidate the underlying molecular mechanisms involved in anwulignan's therapeutic action.

Main Methods:

• Male Sprague-Dawley rats were pretreated with oral anwulignan before inducing II/R injury.
• Mesenteric blood flow, jejunal tissue pathology, smooth muscle function, and various biochemical markers were assessed.
• Key signaling pathways (PI3K/Akt, Nrf2) and apoptosis-related protein expressions were analyzed.

Main Results:

• Anwulignan significantly improved mesenteric blood flow, reduced jejunal congestion and pathological damage.
• It enhanced jejunal smooth muscle tension and acetylcholine reactivity, while increasing antioxidant enzyme activities and acetylcholine levels.
• Anwulignan decreased inflammatory markers, oxidative stress indicators, and modulated the expression of proteins involved in the PI3K/Akt, Nrf2, and apoptosis pathways.

Conclusions:

• Anwulignan effectively ameliorates II/R-induced jejunal injury in rats by reducing inflammation, oxidative stress, and apoptosis.
• The protective effects are mediated through the activation of the PI3K/Akt and Nrf2 signaling pathways.
• Anwulignan shows promise as a potential therapeutic agent for preventing and treating intestinal ischemia/reperfusion injury.